Asteroid Day Gains Momentum with U.S. Recognition from Flagstaff, Coconino County, U.S. Senate, and Vera C. Rubin Observatory Data Release
Since its inception, hundreds of independently organized Asteroid Day events have been taking place globally, calling attention to the critical need for awareness of both the dangers and possibilities associated with asteroids. This year, the movement celebrates official recognition from Flagstaff, Arizona, Coconino County, Arizona, and the United States Senate, marking a pivotal moment in bringing asteroid awareness to the forefront of public consciousness in the USA. Notably, these local, city, and national recognitions are the first in the world to highlight the profound importance of Asteroid Day in inspiring the next generation through Science, Technology, Engineering, Arts, and Mathematics (STEAM) activities.
"As a retired astronaut, I know firsthand the importance of space research. Asteroid Day is a critical initiative that not only raises awareness about planetary defense but also ignites curiosity and inspires the next generation of scientists, engineers, and explorers to pursue careers in STEAM. I'm proud to introduce a resolution recognizing Asteroid Day in the United States Senate," said retired astronaut and U.S. Senator Mark Kelly (D-AZ). The Senate resolution was introduced in partnership with U.S. Senator John Cornyn (R-TX).
"B612 Foundation, as the founding sponsor of Asteroid Day and a leading voice in asteroid analysis and mapping and planetary defense, championed the development of the 100x Declaration, a call to action that launched the global Asteroid Day movement. 'We are humbled and excited to see that in addition to the United Nations recognizing Asteroid Day on 6 December 2016, both Arizona and the United States government are now following suit,' said Danica Remy, Asteroid Day Co-founder and President of B612. 'I am additionally delighted that the US National Science Foundation and Department of Energy Vera Rubin Observatory is using Asteroid Day to release its first data product for scientists and the public. This growing momentum highlights the critical importance of understanding asteroid risks and opportunities for humanity's future."
"This global movement would not have been possible without the visionary leadership of the Government of Luxembourg, particularly the contributions of former Deputy Prime Minister Etienne Schneider, today's CEO of Luxembourg's state innovation agency Luxinnovation Mario Grotz, and today's CEO of Luxembourg Space Agency (LSA) Marc Serres. Their efforts, alongside former NASA Ames Director Pete Worden and former Consul General and Executive Director Luxembourg Trade & Investment San Francisco Georges Schmit, as well as the dedicated leadership of the Asteroid Foundation board of directors, have amplified the Asteroid Day program globally," said Markus Payer, Chair of Asteroid Foundation. "The Luxembourg government's invitation to Asteroid Day co-founders, Apollo 9 astronaut Rusty Schweickart, Danica Remy, Grig Richters and Dr. Brian May, to establish the Asteroid Foundation in Luxembourg in 2017 provided the essential groundwork. This commitment was further solidified by the ongoing leadership of the LSA, which has played an instrumental role in supporting Asteroid Day's global program, alongside Luxembourg's rich local and cross-European in-person year-round initiatives."
Asteroid Day serves as a global platform to educate the public about the exciting prospects of asteroid resource utilization and their role in understanding the origins of our universe, while also covering the role of asteroids in our solar system and the science and technology being developed to detect, track, and ultimately mitigate potential threats.
About Asteroid Foundation: A Luxembourg based nonprofit, founded 2017, is the home of Asteroid Day and is dedicated to promoting public awareness and education about asteroids and space. Through global events, educational initiatives, and strategic partnerships, the Foundation strives to inspire a greater understanding of asteroids and their significance to our planet and humanity's future in space. For more information, visit AsteroidFoundation.org or follow on social: Facebook, LinkedIn or Instagram.
About B612 Foundation: A United States based nonprofit, founded in 2002, develops tools and technologies to understand, map, and navigate our solar system and protect our planet from asteroid impacts through its Asteroid Institute program and supporting educational programs, including Asteroid Day and the Schweickart Prize. Founding Circle and Asteroid Circle members and individual donors from 46 countries support the work financially. For more information, visit B612foundation.org or follow on social: Twitter, Facebook, Linkedin or Bluesky.
View original content:https://www.prnewswire.com/news-releases/asteroid-day-gains-momentum-with-us-recognition-from-flagstaff-coconino-county-us-senate-and-vera-c-rubin-observatory-data-release-302491450.html
SOURCE Asteroid Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Ginkgo Bioworks Reports Second Quarter 2025 Financial Results
Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at Second Quarter 2025 Financial Results Second quarter 2025 Total revenue of $50 million, down from $56 million in the comparable prior year period Second quarter 2025 Cell Engineering revenue of $39 million, up from $36 million in the comparable prior year period, an increase of 8%, primarily driven by growth with biopharma and government customers Second quarter 2025 Biosecurity revenue of $10 million, down from $20 million in the comparable prior year period Second quarter 2025 GAAP net loss of $(60) million, compared to $(217) million in the comparable prior year period Second quarter 2025 Adjusted EBITDA of $(28) million, up from $(99) million in the comparable prior year period, driven by a decrease in operating expenses Cash, cash equivalents and marketable securities balance as of June 30, 2025 of $474 million "Our platform is proving to be a critical engine for AI in biology, with growing demand for our automation and data generation capabilities," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "This is translating into commercial traction, including major new government contracts and expanded service offerings in response to demand in the biopharma industry. This progress is backed by rigorous financial discipline, allowing us to achieve our $250 million annualized cost-reduction goal three months ahead of schedule." Recent Business Highlights & Strategic Positioning Ginkgo's Automation and Datapoints offerings continue to establish themselves as critical tools in AI-powered bioengineering Pacific Northwest National Laboratory (PNNL) selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform, to assist with what is believed to be the largest automated anaerobic system for research in the world Ginkgo launched a new in vitro ADME profiling Service, built on its proprietary RAC automation system. Designed for scale and efficiency, the Service delivers assay quality at cost-effective pricing and includes a price-matching guarantee. By automating traditionally labor-intensive assays and executing them onshore, Ginkgo enables customers to profile more compounds earlier, accelerate decision-making, train AI/ML models, and reduce costs while protecting valuable IP. This launch strengthens Ginkgo's position as a differentiated US-based partner in preclinical R&D analytical services for small molecule drug development. Ginkgo launched its first direct-to-scientist product: a cell-free protein synthesis system This E. coli-based system is optimized for high production from linear DNA, increased solubility of difficult-to-express proteins, and compatibility with automation Ginkgo continues to progress towards its objective to reach Adjusted EBITDA breakeven by the end of 2026 Ginkgo has achieved its target to reach $250 million in annualized cost reduction three months ahead of schedule, through reductions in force and other cost cutting measures. Site consolidation efforts were substantially completed by the year ended 2024, with excess space available for sublease. Full Year 2025 Outlook Ginkgo reaffirms Total revenue of $167-$187 million in 2025 Ginkgo continues to expect Cell Engineering revenue of $117-$137 million in 2025 Ginkgo expects Biosecurity revenue of at least $40 million in 2025 Conference Call DetailsGinkgo will host a videoconference today, Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation will include an overview of the second quarter of 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session. To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation. Ginkgo Investor Website: Audio-Only Dial Ins: +1 646 876 9923 (New York)+1 301 715 8592 (Washington DC)+1 305 224 1968 (Miami)+1 312 626 6799 (Chicago)+1 346 248 7799 (Houston)+1 408 638 0968 (San Jose)+1 564 217 2000 (Seattle)+1 689 278 1000 (Orlando)Webinar ID: 953 3421 4604 If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at for updated dial-in information. About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Forward-Looking Statements of Ginkgo BioworksThis press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, impacts of our restructuring, potential customer success, including successful application of our offerings by our customers, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2025 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. Use of Non-GAAP Financial MeasuresCertain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo Bioworks Contacts: INVESTOR CONTACT:investors@ MEDIA CONTACT:press@ Ginkgo Bioworks Holdings, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share data) As of June 30, 2025As of December 31, 2024 AssetsCurrent assets:Cash and cash equivalents $ 203,566$ 561,572 Marketable securities 270,125— Accounts receivable, net 22,15221,857 Accounts receivable - related parties 974586 Prepaid expenses and other current assets 26,20818,729 Total current assets 523,025602,744 Property, plant and equipment, net 186,354203,720 Operating lease right-of-use assets 375,796394,435 Investments 32,66248,704 Intangible assets, net 66,15272,510 Other non-current assets 47,02055,336 Total assets $ 1,231,009$ 1,377,449 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable $ 11,202$ 14,169 Deferred revenue (includes $311 and $795 from related parties) 28,28727,710 Accrued expenses and other current liabilities 57,23165,387 Total current liabilities 96,720107,266 Non-current liabilities:Deferred revenue, net of current portion (includes $64,786 and $72,260 from related parties) 74,56698,783 Operating lease liabilities, non-current 428,827438,766 Other non-current liabilities 17,94416,576 Total liabilities 618,057661,391 Commitments and contingencies (Note 10)Stockholders' equity:Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued —— Common stock, $0.0001 par value (Note 8) 65 Additional paid-in capital 6,600,1076,555,416 Accumulated deficit (5,988,814)(5,837,557) Accumulated other comprehensive income (loss) 1,653(1,806) Total stockholders' equity 612,952716,058 Total liabilities and stockholders' equity $ 1,231,009$ 1,377,449 The accompanying notes are an integral part of these condensed consolidated financial statements. Ginkgo Bioworks Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share data) Three Months Ended June 30,Six Months Ended June 30,2025202420252024 Cell Engineering revenue (1) $ 39,134$ 36,205$ 77,364$ 64,094 Biosecurity revenue 10,47020,00120,55830,056 Total revenue 49,60456,20697,92294,150 Costs and operating expenses:Cost of Biosecurity revenue 9,44211,80717,39921,009 Cost of other revenue 5,3801,9149,4701,914 Research and development 53,370134,221124,293270,678 General and administrative 43,27966,28592,322136,572 Goodwill impairment —47,858—47,858 Restructuring charges 3,67417,0668,94717,066 Total operating expenses 115,145279,151252,431495,097 Loss from operations (65,541)(222,945)(154,509)(400,947) Other income (expense):Interest income, net 6,08310,31312,16422,024 Loss on investments (229)(6,826)(3,922)(9,370) Change in fair value of warrant liabilities —3,233—4,173 Other income (expense), net (896)(766)(5,185)1,249 Total other income 4,9585,9543,05718,076 Loss before income taxes (60,583)(216,991)(151,452)(382,871) Income tax (benefit) expense (283)190(195)221 Net loss $ (60,300)$ (217,181)$ (151,257)$ (383,092) Net loss per share:Basic $ (1.10)$ (4.23)$ (2.77)$ (7.55) Diluted $ (1.10)$ (4.23)$ (2.77)$ (7.56) Weighted average common shares outstanding:Basic 54,858,98251,370,02954,552,00650,740,744 Diluted 54,858,98251,375,59954,552,00650,746,314 Comprehensive loss:Net loss $ (60,300)$ (217,181)$ (151,257)$ (383,092) Other comprehensive (loss) income:Foreign currency translation adjustment 2,586(172)3,435(3,207) Unrealized gains (loss) on available-for-sale securities (83)—24— Total other comprehensive (loss) income 2,503(172)3,459(3,207) Comprehensive loss $ (57,797)$ (217,353)$ (147,798)$ (386,299) (1) Includes related party revenue of $420 and $5,146 for the three months ended June 30, 2025 and 2024, respectively, and $8,518 and $5,819 for the six months ended June 30, 2025 and 2024, respectively. Ginkgo Bioworks Holdings, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Six Months Ended June 30,20252024 Cash flows from operating activities:Net loss $ (151,257)$ (383,092) Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization 31,15930,199 Stock-based compensation 42,67877,928 Goodwill impairment —47,858 Restructuring related impairment charges —4,823 Loss on investments 3,9589,370 Change in fair value of notes receivable 5,2851 Change in fair value of warrant liabilities —(4,173) Change in fair value of contingent consideration (4,232)2,284 Non-cash lease expense 14,86613,070 Non-cash in-process research and development —19,795 Other non-cash activity 462,096 Changes in operating assets and liabilities:Accounts receivable (412)(1,102) Prepaid expenses and other current assets (2,272)1,770 Operating lease right-of-use assets 3,81414,373 Other non-current assets (125)(833) Accounts payable, accrued expenses and other current liabilities (5,125)10,864 Deferred revenue, current and non-current ($7,958) and ($4,577) from related parties (23,676)(17,012) Operating lease liabilities, current and non-current (11,638)(3,866) Other non-current liabilities 5,1561,998 Net cash used in operating activities (91,775)(173,649) Cash flows from investing activities:Purchases of marketable debt securities (320,132)— Maturities of marketable debt securities 64,958— Purchases of property and equipment (7,660)(33,742) Business acquisition —(5,400) Other 262191 Net cash used in investing activities (262,572)(38,951) Cash flows from financing activities:Proceeds from exercise of stock options —84 Principal payments on finance leases (305)(494) Contingent consideration payment —(661) Net cash used in financing activities (305)(1,071) Effect of foreign exchange rates on cash and cash equivalents 260(173) Net decrease in cash, cash equivalents and restricted cash (354,392)(213,844) Cash and cash equivalents, beginning of period 561,572944,073 Restricted cash, beginning of period 44,17145,511 Cash, cash equivalents and restricted cash, beginning of period 605,743989,584 Cash and cash equivalents, end of period 203,566730,367 Restricted cash, end of period 47,78545,373 Cash, cash equivalents and restricted cash, end of period $ 251,351$ 775,740 Ginkgo Bioworks Holdings, Inc. Segment Information (in thousands, unaudited) Three Months Ended June 30,Six Months Ended June 30,2025 202420252024 Cell Engineering Revenue $ 39,134 $ 36,205$ 77,364$ 64,094 Costs and operating expenses: Cost of other revenue 3,865 1,9146,9861,914 Research and development 31,065 84,11379,735166,011 General and administrative 14,141 33,20232,16871,446 Cell Engineering operating loss (9,937) (83,024)(41,525)(175,277) Biosecurity Revenue 10,470 20,00120,55830,056 Costs and operating expenses: Cost of Biosecurity revenue 8,583 11,80715,80621,009 Research and development — 458—578 General and administrative 6,702 11,17914,75123,130 Biosecurity operating loss (4,815) (3,443)(9,999)(14,661) Total segment operating loss (14,752) (86,467)(51,524)(189,938) Reconciling items to reconcile total segment operating loss to loss before income taxes: Stock-based compensation (1) 22,526 38,22643,32680,623 Goodwill impairment — 47,858—47,858 Depreciation and amortization 15,793 17,33031,15930,199 Restructuring charges (2) 3,674 17,0668,94717,066 Carrying cost of excess space (net of sublease income) (3) 12,413 7,38324,0887,383 Merger and acquisition related expense (income) (4) (3,617) 4,512(4,535)6,906 Acquired in-process research and development — 2,978—19,849 Other (income) expense, net (5) (4,958) (4,829)(3,057)(16,951) Loss before income taxes $ (60,583) $ (216,991)$ (151,452)$ (382,871) (1) Includes $0.3 million and $1.1 million in employer payroll taxes for the three months ended June 30, 2025 and 2024, respectively, and $0.6 million and $2.7 million in employer payroll taxes for six months ended June 30, 2025 and 2024, respectively. (2) See Note 3, Restructuring, for composition of costs. (3) The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces. (4) Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. (5) Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses. Ginkgo Bioworks Holdings, Inc. Selected Non-GAAP Financial Measures (in thousands, unaudited) Three Months Ended June 30,Six Months Ended June 30, (in thousands) 2025202420252024 Net loss (1) $ (60,300)$ (217,181)$ (151,257)$ (383,092) Interest income, net (6,083)(10,313)(12,164)(22,024) Income tax (benefit) expense (283)190(195)221 Depreciation and amortization 15,79317,33031,15930,199 EBITDA (50,873)(209,974)(132,457)(374,696) Stock-based compensation (2) 22,52638,22643,32680,623 Goodwill impairment —47,858—47,858 Restructuring charges (3) 3,67417,0668,94717,066 Merger and acquisition related expense (income) (4) (3,617)4,512(4,535)6,906 Loss on investments 2296,8263,9229,370 Change in fair value of warrant liabilities —(3,233)—(4,173) Change in fair value of convertible notes —(480)5,285846 Adjusted EBITDA $ (28,061)$ (99,199)$ (75,512)$ (216,200) (1) All periods include non-cash revenue when earned, including $7.5 million recognized in the six months ended June 30, 2025, pursuant to the release of deferred revenue related to the mutual termination of a customer agreement. (2) Includes $0.3 million and $1.1 million in employer payroll taxes for the three months ended June 30, 2025 and 2024, respectively, and $0.6 million and $2.7 million for the six months ended June 30, 2025 and 2024, respectively. (3) Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024. (4) Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero and $3.0 million for the three months ended June 30, 2025 and 2024, respectively, and zero and $19.8 million for the six months ended June 30, 2025 and 2024, respectively. View original content to download multimedia: SOURCE Ginkgo Bioworks Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
4 days ago
- Yahoo
NOVEL IMMUNOLOGIC SURVEILLANCE STUDY PROVIDES NEW INSIGHTS INTO POST-PANDEMIC RETURN OF RESPIRATORY VIRUSES
Ongoing clinical research study in US children documents the rebound of endemic respiratory viruses, builds foundation for expediting future vaccines and treatments AURORA, Colo., Aug. 7, 2025 /PRNewswire/ -- The first paper from a multi-year clinical research study has been published in The Lancet Infectious Diseases: Dynamics of Endemic Virus Re-emergence in Children in the USA Following the COVID-19 Pandemic (2022-2023): A Longitudinal Immunoepidemiologic Surveillance Study and demonstrates how the approach can improve modeling to better predict future outbreaks. The paper shares findings from a multicenter clinical research study, one of many studies that are part of the recently launched PREMISE (Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology) program, led by Dr. Daniel Douek at the National Institutes of Health's (NIH) Vaccine Research Center (VRC). Data collected during the first year of the PREMISE study, 2022-2023, shows for the first time how non-pharmaceutical interventions such as masking and distancing targeted towards SARS-CoV-2 during the pandemic also decreased circulation rates of and population immunity to common respiratory pathogens in children. The study provides new evidence-based insight into what was driving the large post-pandemic rebound in these diseases and enables more accurate predictions for the future. This study is a partnership between PREMISE and clinical research sites at academic institutions led by principal investigator Kevin Messacar, MD, PhD, infectious disease specialist at Children's Hospital Colorado, at the central site at University of Colorado Anschutz Medical Campus and Children's Hospital Colorado with additional study sites at University of North Carolina, Weill Cornell Medicine and the University of Alabama at Birmingham. The PREMISE study conducted immunologic surveillance on children younger than 10 years old, by enrolling them and following them for over a year. Through repeat blood sampling, the team could determine what children at varying young ages had immunity to and what they were susceptible to. Through respiratory sampling during illness, researchers were able to determine what infections they experienced. The data showed that most younger children lacked immunity to many normal respiratory viruses during the pandemic, suggesting they had not been exposed, as they typically would have, due to prevention measures in place. Following the lifting of pandemic measures, the level of immunity rose across all pathogens studied, reflective of the unprecedented widespread resurgence of these viruses in children after the end of the pandemic. While most research studies target a specific disease, samples from PREMISE were tested for many common and emerging respiratory viruses, including RSV, influenza and enterovirus D68 (EV-D68), which can cause the polio-like illness, acute flaccid myelitis. The data allowed experts to recreate past circulation patterns and model predictions for future outbreaks with greater accuracy and precision. They showed that PREMISE data from 2022-23 could be used to accurately predict the subsequent wave of disease of the emerging pathogen EV-D68 that occurred in 2024. "Four cohorts of almost 1,000 children have provided an invaluable bank of samples and data," said lead author Hai Nguyen-Tran, MD, infectious disease specialist at Children's Hospital Colorado and assistant professor at University of Colorado School of Medicine. "These are being used to develop 'on the shelf' medical countermeasures, such as antibody treatments and vaccines, for pathogens of interest. Instead of starting from scratch, this study gives us a head start to understand, predict and prepare for future pandemics." Samples and data from the PREMISE study will also be used to learn which parts of viruses the human immune system attacks to become immune, so teams can better design new antibody treatments and effective vaccines to mimic this response. "In the future, this type of immune surveillance can be used to better understand the impact of public interventions on population immunity and future waves of disease," said Dr. Messacar, who is also a professor at University of Colorado School of Medicine. "PREMISE is a great example of a successful research partnership between NIH scientists and clinical researchers in academia, leading to concrete deliverables such as vaccine candidates and monoclonal antibodies that can directly impact public health." This study is fully funded by a subcontract with Frederick National Laboratory for Cancer Research (FNLCR), currently operated by Leidos Biomedical Research, Inc. through Agreement 21X192QT1. FNLCR funding was provided by the NIH Vaccine Research Center within NIAID. The total project funding is $7.98 million over five years. No financing for this project was supplied by nongovernmental sources. ABOUT CHILDREN'S HOSPITAL COLORADOChildren's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Media Contact: Rachael Fowler, Children's Hospital Colorado 24/7 media line: 303-890-8314media@ View original content to download multimedia: SOURCE Children's Hospital Colorado
Yahoo
5 days ago
- Yahoo
New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation
Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing late complications HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Following the unveiling of 12-month follow-up results from the pivotal Bridge to HOPE trial during the World Transplant Congress (WTC) 2025 Plenary Session, additional analyses of the data demonstrate that Hypothermic Oxygenated Perfusion (HOPE), in conjunction with the VitaSmartTM Perfusion System, can provide significant cost-savings for hospital systems without compromising quality of care, and reduce the severity of organ rejection, including steroid resistant rejection. The results of these analyses were presented in oral abstract sessions by David Axelrod, MD, University Hospitals Cleveland Medical Center, OH ("Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation") and David J. Reich, MD, FACS, Drexel University, Philadelphia, PA ("Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation"). The data were part of the 12-month follow-up study of the Bridge to Life Ltd. Bridge to Hope clinical trial (HOPE with VitaSmartTM Machine Perfusion System). "Building on the 12‑month follow‑up Bridge to HOPE clinical trial data presented in the Plenary Session, these additional analyses further strengthen the evidence for the value that HOPE used with the VitaSmart™ Perfusion System brings to the transplant community," said Don Webber, CEO and President of Bridge to Life Ltd., sponsor of the Bridge to HOPE clinical trial. "Bridge to Life is committed to partnering with Transplant Centers, Organ Procurement Organizations, and Hospitals to lower total cost of care while delivering the highest‑quality patient outcomes—by shortening hospital stays and reducing post‑transplant complications, including the risk of severe and steroid‑resistant rejection. Our broad presence at WTC 2025 underscores our leadership in advancing transplant science." In the economic analysis, compared with standard static cold storage (SCS), liver transplantation using HOPE reduced initial post-liver transplantation hospital length of stay (10.8 vs. 12.9 days), costs associated with biliary complications (20.2% vs. 24.6%), re-transplants (1.8% vs. 4.5%), and death (2.8% vs. 3.6%). Further, HOPE reduced one-year post-transplant costs by an average of $28,565, according to Centers for Medicare & Medicaid Services (CMS) data. Researchers concluded that HOPE for a minimum 1.5 hours at the recipient hospital reduced the cost of liver transplantation by shortening the index hospitalization and decreasing late complications. Additional financial benefits may include increased organ utilization, reduced staff overtime, and fewer high Model for End-Stage Liver Disease (MELD) transplants. In the review of the organ rejection data, moderate/severe biopsy-proven organ rejection was less common in HOPE than SCS (32% v 67%, p=.033). Ten patients developed steroid resistant organ rejection: one in the HOPE cohort and nine in the SCS group (4% v 43%, p=.003). Researchers concluded that while the prevalence of organ rejection was similar in HOPE and SCS, HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection. These results highlight the immunomodulatory benefits of HOPE and warrant further research. About Bridge to Life™ LtdBridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally. 1VitaSmart™ is CE Marked and available for sale in several markets outside of the United States. VitaSmart™ is pending FDA approval in the United States. View original content to download multimedia: SOURCE Bridge to Life, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
